Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government ...

Drugmaker Merck , known as MSD outside of the U.S. and Canada, expects to increase its workforce across its India sites by ...

Merck (MRK) ended the recent trading session at $92.25, demonstrating a +1.84% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily gain of 1.59%.

Investors can approximate the average market return by buying an index fund. When you buy individual stocks, you ...

Epitopea, an Anglo-Canadian company developing accessible, off-the-shelf RNA-based immunotherapies for cancer, has announced a license and research collaboration deal with US pharma giant Merck & Co ...

To be notified if a class action against Merck & Co., Inc. settles or to receive free alerts when corporate executives engage ...

These stocks have dropped below the significant moving averages where it’s easy to make out the direction of trend, near-term ...

From STAT’s Matthew Herper: Eikon Therapeutics, the cell-biology-focused startup run by former Merck R&D head Roger ...

Merck (NYSE:MRK) just took a major hit ... GuruFocus has detected 1 Warning Sign with NVO. The company's 2025 forecast didn't help either. Revenue guidance of $64.1 billion to $65.5 billion ...

For now, Moderna may be a good stock to put on a watch list, but it's likely too risky and volatile for the vast majority of ...

Merck on Tuesday issued full-year 2025 revenue guidance that fell short of Wall Street's expectations. The company said that sales range reflects a decision to halt shipments of Gardasil, a ...

President Donald Trump and DOGE leader Elon Musk sit down with 'Hannity' in an exclusive interview airing Tuesday. The Investment Committee debate the Calls of the Day in two biotech names. A group of ...